These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 16722814)

  • 41. nab-Paclitaxel dose and schedule in breast cancer.
    Martín M
    Breast Cancer Res; 2015 Jun; 17(1):81. PubMed ID: 26067995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nab-paclitaxel in patients with metastatic melanoma.
    Leon-Ferre RA; Markovic SN
    Expert Rev Anticancer Ther; 2015; 15(12):1371-7. PubMed ID: 26536477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
    Gupta N; Hatoum H; Dy GK
    Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
    Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
    Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ABI 007.
    Drugs R D; 2004; 5(3):155-9. PubMed ID: 15139776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    Liu M; Liu S; Yang L; Wang S
    BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
    Montana M; Ducros C; Verhaeghe P; Terme T; Vanelle P; Rathelot P
    J Chemother; 2011 Apr; 23(2):59-66. PubMed ID: 21571619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
    Yamada C; Yonezawa M; Shimizu Y; Taga R; Kashihara H; Tsuji K; Murata T; Yoshino H
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):77-81. PubMed ID: 24423956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
    Marschner N; Salat C; Söling U; Hansen R; Grebhardt S; Harde J; Nusch A; Potthoff K
    Clin Breast Cancer; 2018 Dec; 18(6):e1323-e1337. PubMed ID: 30100104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
    BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
    Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
    Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer.
    Yang D; Xu G; Ding H; Zhong L; Zhu J; Mi X; Xin W; Zhou T; Wang J; Fang L
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):523-534. PubMed ID: 39080018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
    Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
    J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
    Stage TB; Bergmann TK; Kroetz DL
    Clin Pharmacokinet; 2018 Jan; 57(1):7-19. PubMed ID: 28612269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
    Zong Y; Wu J; Shen K
    Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
    Kudlowitz D; Muggia F
    Expert Opin Drug Saf; 2014 Jun; 13(6):681-5. PubMed ID: 24749649
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
    Alba E; Ciruelos E; López R; López-Vega JM; Lluch A; Martín M; Muñoz M; Sánchez-Rovira P; Seguí MÁ; Liria MR; Pérez-Alcántara F
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):381-91. PubMed ID: 23534988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    He F; Liu J; Shen X; Wang Z; Li Q; Li G
    Ann Pharmacother; 2022 Aug; 56(8):898-909. PubMed ID: 34963337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
    Chao TC; Chu Z; Tseng LM; Chiou TJ; Hsieh RK; Wang WS; Yen CC; Yang MH; Hsiao LT; Liu JH; Chen PM
    Invest New Drugs; 2005 Mar; 23(2):171-7. PubMed ID: 15744594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.